Adaptive Cash Conversion Cycle from 2010 to 2024

ADPT Stock  USD 6.46  0.00  0.00%   
Adaptive Biotechnologies Cash Conversion Cycle yearly trend continues to be comparatively stable with very little volatility. Cash Conversion Cycle is likely to outpace its year average in 2024. From the period from 2010 to 2024, Adaptive Biotechnologies Cash Conversion Cycle quarterly data regression had r-value of  0.44 and coefficient of variation of  20.07. View All Fundamentals
 
Cash Conversion Cycle  
First Reported
2010-12-31
Previous Quarter
113.89764505
Current Value
156.74
Quarterly Volatility
26.57485306
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Adaptive Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptive Biotechnologies' main balance sheet or income statement drivers, such as Interest Income of 14.2 M, Discontinued Operations of 0.0 or Depreciation And Amortization of 13.1 M, as well as many indicators such as Price To Sales Ratio of 3.95, Dividend Yield of 0.0 or PTB Ratio of 2.41. Adaptive financial statements analysis is a perfect complement when working with Adaptive Biotechnologies Valuation or Volatility modules.
  
Check out the analysis of Adaptive Biotechnologies Correlation against competitors.

Latest Adaptive Biotechnologies' Cash Conversion Cycle Growth Pattern

Below is the plot of the Cash Conversion Cycle of Adaptive Biotechnologies Corp over the last few years. It is Adaptive Biotechnologies' Cash Conversion Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptive Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
Cash Conversion Cycle10 Years Trend
Slightly volatile
   Cash Conversion Cycle   
       Timeline  

Adaptive Cash Conversion Cycle Regression Statistics

Arithmetic Mean132.40
Geometric Mean130.38
Coefficient Of Variation20.07
Mean Deviation19.04
Median118.82
Standard Deviation26.57
Sample Variance706.22
Range98.7649
R-Value0.44
Mean Square Error615.06
R-Squared0.19
Significance0.10
Slope2.60
Total Sum of Squares9,887

Adaptive Cash Conversion Cycle History

2024 156.74
2023 113.9
2022 119.04
2021 159.3
2020 212.66
2019 130.03
2018 143.7

About Adaptive Biotechnologies Financial Statements

Adaptive Biotechnologies shareholders use historical fundamental indicators, such as Cash Conversion Cycle, to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may analyze each financial statement separately, they are all interrelated. The changes in Adaptive Biotechnologies' assets and liabilities, for example, are also reflected in the revenues and expenses on on Adaptive Biotechnologies' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cash Conversion Cycle 113.90  156.74 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Adaptive Stock Analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.